Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecan

Japanese Journal of Clinical Oncology

Volumn 37, Issue 5, 2007, Pages 358-364

  Fujiwara, Yutaka ^a   Sekine, Ikuo ^a   Ohe, Yuichiro ^a   Kunitoh, Hideo ^a   Yamamoto, Noboru ^a   Nokihara, Hiroshi ^a   Simmyo, Yuko ^a   Fukui, Tomoya ^a   Yamada, Kazuhiko ^a   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Irinotecan; Lung cancer; Toxicity

Indexed keywords

BILIRUBIN; CISPLATIN; IRINOTECAN;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; LIVER METASTASIS; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; PREDICTION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIRUBIN; CAMPTOTHECIN; CISPLATIN; DIARRHEA; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES;

EID: 34547904690     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym033     Document Type: Article

References (28)

1. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991;83:1164-8.
2. Rothenberg ML, Kuhn JG, Burris HA, Nelson J, 3rd, Eckardt JR, Tristan-Morales M, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993;11:2194-204.
3. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14.
4. Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N, et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 2003;88:335-41.
5. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Roleof uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998;101:847-54.
6. Ando Y, Saka H, Ando M, Sawa T, Moro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res 2000;60:6921-6.
7. Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002;62: 608-17.
8. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-8.
9. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, et al. UGT A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002;2:43-7.
10. Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004;91:678-82.
11. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients. Clin Cancer Res 2004;10:5151-9.
12. Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, et al. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 1992;10:1775-80.
13. Masuda N, Fukuoka M, Fujita A, Kurita Y, Tsuchiya S, Nagao Y, et al. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group. Br J Cancer 1998;78:251-6.
14. Niho S, Nagao K, Nishiwaki Y, Yokoyama A, Saljo N, Ohashi Y, et al. Randomized multicenter phase III trial of irinotecan and cisplatin versus cisplatin and vindesine in patients with advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 1999;18:p492a.
15. Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Takifuji N, et al. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 1993;68:777-82.
16. Kudoh S, Fujiwara Y, Takada Y, Yamamoto H, Kinoshita A, Ariyoshi Y, et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 1998;16:1068-74.
17. Burchell B, Hume R. Molecular genetic basis of Gilbert's syndrome. J Gastroenterol Hepatol 1999; 14:960-6.
18. Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H, et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004;75:501-15:
19. Jinno H, Tanaka-Kagawa T, Hanioka N, Saeki M, Ishida S, Nishimura T, et al. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos, 2003;31: 108-13.
20. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12: 360-7.
21. Arnold RJ, Gabrail N, Raut M, Kim R, Sung JC, Zhou Y. Clinical implications of chemotherapy-induced diarrhea in patients with cancer. J Support Oncol 2005;3:227-32.
22. Mathijssen RH, Loos WJ, Verweij J, Sparreboom A. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2002;2:103-23.
23. Yokoi T, Narita M, Nagai E, Hagiwara H, Aburada M, Kamataki T. Inhibition of UDP-glucuronosyltransferase by aglycons of natural glucuronides in kampo medicines using SN-38 as a substrate. Jpn J Cancer Res 1995;86:985-9.
24. Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11, Jpn J Cancer Res 1993;84:697-702.
25. Venook AP, Enders Klein C, Fleming G, Hollis D, Leichman CG, et al. A phase I, and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction orwith prior pelvic radiation: CALGB 9863: Ann Oncol 2003;14:1783-90.
26. Schaaf U, Hammond LA, Tipping SJ, Goldberg RM, Goel R, Kuhn JG, et al. Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction. Clin Cancer Res 2006;12:3782-91.
27. Sartor RB. Mucosal immunology and mechanisms of gastrointestinal inflammation. In: Feldman M, Friedman LS, Sleisenger MH editors. Gastrointestinal and Liver Disease, 7th edn. Philadelphia, PA: Saunders 2002; 21-51.
28. Balducci L, Little DD, Glover NG, Hardy CS, Steinberg MH. Granulocyte reserve in cancer and malnutrition. Ann Intern Med 1983;98:610-1.